This one is worth going through line by line, because the reasoning contains a category error — and because the best way forward is probably not the one the letter invites you toward.
"Evenity is not FDA approved for osteoporosis in males. The drug is not listed in AHFS-DI or DrugDex. Therefore this drug is not a Medicare Part D drug."
Take the statements one at a time:
Evenity was never a Part D drug in the first place — it is a Part B drug. It's given as two subcutaneous injections once a month by a healthcare provider in an office, billed under HCPCS code J3111 on a medical claim form, not dispensed from a pharmacy for self-injection.
Under Medicare's rules, a drug is a Part D drug only if Part B payment is not available for it. Physician-administered drugs are carved out of Part D by statute. Whether an injectable falls on one side or the other is determined by the regional Medicare contractor's Self-Administered Drug exclusion list — for Texas, that's Novitas Solutions Jurisdiction H, Article A53127. Romosozumab does not appear on that list. Part B payment is available, so it cannot be a Part D drug.
So the letter reached a correct Part D conclusion by applying a Part D test — to a drug that was never in that benefit. The Part B question, which is the one that actually governs, was never asked or answered.
This isn't an interpretation you have to argue for. Two current UHC publications treat Evenity as a Part B drug:
UnitedHealthcare cannot coherently run Evenity through its own Medicare Part B step therapy program under a J-code and simultaneously deny it as "not a Part D drug." That's a documented internal contradiction, in their own published policies, and it's the cleanest thing in this entire file.
It isn't a technicality. The two benefits apply fundamentally different standards to off-label use.
| Part D — what they applied | Part B — what should apply | |
|---|---|---|
| What counts as acceptable off-label support | Only two named compendia: AHFS-DI and DRUGDEX. A closed list, set by statute. | "The major drug compendia, authoritative medical literature and/or accepted standards of medical practice" |
| Do clinical guidelines count? | No | Yes |
| Does peer-reviewed literature count? | No — except for cancer drugs | Yes, independently |
| Governing authority | Social Security Act §1927(g)(1)(B)(i) | Medicare Benefit Policy Manual, Ch. 15, §50.4.2 |
And Medicare Advantage plans don't get to opt out of this. 42 CFR 422.101(b) requires them to follow national coverage determinations, the local Medicare contractor's coverage decisions, and the general coverage conditions of traditional Medicare. A plan cannot apply a narrower off-label standard to a Part B drug than traditional Medicare would.
If the Part B standard applies, there is real published evidence to point at:
Three things temper this, and it's better to know them before spending months on it than after.
Once Evenity is correctly on the Part B track, it lands in UnitedHealthcare's Part B step therapy program, where the preferred agents are Prolia and its biosimilars (denosumab) and Evenity is non-preferred. To get a non-preferred agent approved you must show one of:
And their position here is stronger than usual, because denosumab has carried an FDA-approved indication for men since September 2012. They'd be asking him to try a drug that is on-label for men and guideline-supported, before one that is off-label with a boxed warning.
So any new submission must address both gates at once — the benefit-category error and a step-therapy exception. Addressing only the first just produces a second denial.
One useful limit: under 42 CFR 422.136, step therapy may be applied only to new administrations, with at least a 365-day lookback. If he's had any of these agents within the past year, step therapy may not lawfully be applied at all.
The legal architecture is strong. The clinical picture is more mixed, and it's worth being straight about it.
Evenity carries a boxed warning for heart attack, stroke, and cardiovascular death, and should not be started in anyone who has had a heart attack or stroke in the preceding year. The BRIDGE trial itself showed a cardiovascular imbalance — 4.9% versus 2.5% — in a study not powered to measure it. And the 2024 ESCEO/IOF men's guideline, while it discusses romosozumab, names abaloparatide — not romosozumab — as the appropriate first-line anabolic for men at very high risk, and explicitly flags the cardiovascular consideration.
A reviewer applying the Part B standard in good faith could conclude that the literature does support romosozumab in men and that an on-label alternative should come first. If there is any cardiovascular history, this is the hardest drug in the class on which to fight a coverage battle.
The 60-day appeal window closed long ago. Good-cause extensions for late filing exist and have no stated outer limit, and one recognized ground — "incorrect or incomplete information from the plan about how to appeal" — arguably fits a letter that never mentioned a Part B pathway existed. But 18 months is a long reach.
The better move is not to appeal at all. File a new prior authorization request under the medical/Part B benefit. The February 2025 determination decided only a Part D question; the Part B question was never adjudicated, so this isn't re-litigating anything. There's no rule barring a fresh request, and it produces a new, fully appealable determination with a clean 60-day clock and access to the entire appeal ladder.
Tymlos (abaloparatide) has carried an FDA-approved indication for men since December 2022, with no qualifying language: "to increase bone density in men with osteoporosis at high risk for fracture… or patients who have failed or are intolerant to other available osteoporosis therapy." A man with congenital osteoporosis, long bisphosphonate exposure, and fractures meets both prongs.
Because it's FDA-approved for men, the entire compendia question evaporates — there's nothing to argue. And Tymlos runs through the Part D pharmacy benefit, so there's no benefit-track dispute and no Part B step therapy program to clear. It becomes an ordinary prior authorization request.
Whether it's the right drug is a clinical question for the physician, not a coverage question. But it's worth putting the coverage reality in front of them: this request is dramatically easier to win, and the guideline that addresses men specifically names abaloparatide as the first-line anabolic for men at very high risk.
If there's a clinical reason it has to be Evenity — the dual mechanism, the fixed 12-month course rather than daily self-injection, or a blunted response to PTH-analog anabolics after long bisphosphonate exposure — then refile properly:
If any doses were paid out of pocket, submit a request for reimbursement to the plan. That generates its own determination with a fresh 60-day appeal window. One caution: Medicare's general claim-filing limit is one year from the date of service, and how strictly plans apply that to member reimbursement requests varies. If those doses are more than a year old, treat reimbursement as at risk — and submit now rather than waiting for the coverage fight to resolve.
Ask the plan to identify the specific compendium and coverage provision it relied on, and ask for the published internal coverage criteria. Under 42 CFR 422.101(b)(6), plans may use internal criteria only where Medicare's criteria aren't fully established, and must publish them with the supporting evidence.
The prescribing office writes this, not the patient. These are the two paragraphs that carry the weight.
The letter asserts that romosozumab isn't listed in AHFS-DI or DRUGDEX for use in men. Both are subscription databases that couldn't be checked directly here. A hospital pharmacist or medical librarian can look this up in minutes. If DRUGDEX does carry a supporting citation for men, the original Part D denial was substantively wrong on its own terms as well — which would make the whole thing considerably easier. It's a five-minute check with real upside.